Finland, April 15 -- The European Investment Bank (EIB) is lending €100 million to Finnish pharmaceutical company Orion Pharma to develop new treatments for cancer, pain and other serious conditions with few treatment options.The financing will support Orion Pharma's research and development activities across its European centres, covering personnel costs, clinical trials, patenting and investments in specialised laboratory equipment. By reinforcing Orion Pharma's long-term R&D capacity, the EIB is helping strengthen Europe's competitiveness in advanced biopharmaceutical innovation. The project also contributes to the EU's strategic goal of enhancing supply security for essential medicines. Orion Pharma is a key producer of active pha...